A small biotech company is aiming to recharge tired cells, giving mitochondrial disease patients new hope of a disease-specific treatment.
“We focus on patients, going after disease with high unmet needs, like primary mitochondrial myopathies,” Niall O’Donnell, Ph.D., President, CEO and Director of Reneo Pharmaceuticals, told BioSpace.
